Development of a thermostable SARS-CoV-2 variant-based bivalent protein vaccine with cross-neutralizing potency against Omicron subvariants.
Wang R, Huang X, Cao T, Sun C, Luo D, Qiu H, Wu M, Huang X, Yu C, Li J, Kong D, Ma J, Zhang X, Hu P, Zhang Y, Luo C, Zhao H, Li Y, Deng Y, Qin C, Xie L.
Wang R, et al. Among authors: zhang x, zhang y.
Virology. 2022 Nov;576:61-68. doi: 10.1016/j.virol.2022.09.003. Epub 2022 Sep 20.
Virology. 2022.
PMID: 36174448
Free PMC article.